Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination
| Autor: | Seiji Satoh, Suguru Hasegawa, Satoshi Nagayama, Go Watanabe, Masanori Fukushima, Arimichi Takabayashi, Nobuhiro Ozaki, Hiroshi Okabe, Yoshiharu Sakai |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Stomach Neoplasms Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Aged Retrospective Studies Tegafur Aged 80 and over Cisplatin Chemotherapy business.industry Standard treatment Gastroenterology Induction chemotherapy General Medicine Middle Aged Prognosis medicine.disease Primary tumor Neoadjuvant Therapy Survival Rate Clinical trial Drug Combinations Oxonic Acid Chemotherapy Adjuvant Feasibility Studies Female business medicine.drug |
| Zdroj: | Gastric Cancer. 9:129-135 |
| ISSN: | 1436-3305 1436-3291 |
| DOI: | 10.1007/s10120-006-0369-4 |
| Popis: | Standard treatment for highly advanced gastric cancer (AGC) has not been established yet. Neoadjuvant chemotherapy (NAC) represents a promising approach, which may improve the prognosis of AGC. In this study, we analyzed the feasibility and efficacy of NAC with S-1 (TS-1)/cisplatin CDDP in order to design appropriate clinical trials for AGC. Results for a series of 45 consecutive patients with AGC treated with S-1/CDDP induction chemotherapy since January 2002 were analyzed retrospectively. The primary tumor was resected in 36 of the 45 patients (resectability, 80.0%). Progression of the disease during chemotherapy was observed in 1 patient only (2.2%). No treatment-related deaths occurred, and serious adverse effects (grade 3–4) were noted in only 2.2% of the patients. The overall median survival time was 1.82 years. Especially noteworthy is that, in patients with highly advanced disease (pretreatment [c]-stage IV; n = 27), resectability was 66.7% and curative (R0) resection was possible in 10 patients. The median survival times for c-stage IV patients who had total, curative, and noncurative resections were 20.8, 22.3 and 12.6 months, respectively. R0 resection was possible for all c-stage III patients (n = 17), with a 2-year overall survival of 90.9%. The downstaging rate was 55.6% (20/36), resulting in a significantly improved prognosis for the downstaged patients (P = 0.012). Induction chemotherapy using S-1/CDDP for AGC appears to be a safe and promising treatment. We have therefore started two independent multiinstitutional clinical trials to evaluate the efficacy of this treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink